Drugs / Allogenic islet cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01241864 | Dec 2010 → Dec 2026 expected | type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01630850 | May 2012 → Jun 2030 expected | type 1 diabetes mellitus | University of Chicago | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic islet cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01630850 ↗ |
| Modality | Cell therapy | “Human allogenic islet cells.” NCT01241864 ↗ |
| Route | Other | “Intraportal infusion of islet cell through the portal vein in the liver.” NCT01241864 ↗ |